anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The children will be asked which cartoon they want to watch before the procedure. They will start to watch the cartoon 3 minutes before the procedure.
Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute. Then, the researcher made the second vein assessment and inserted a 20-G peripheral catheter into the inner surface of the forearm.
In this phase I study, patients will receive intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC with total volumes for each intradermal injection of no more than 1 ml to be split into four injections of 0.25 ml each in four limbs in node draining areas (proximal arms and thighs), for a total DC dose of 2 X 10\^6, 10\^7 or 2 X 10\^7 cells to be administered intradermally. DC injections in one course of therapy will be given four times at intervals of weekly for two doses (days 1 and 8 +/- 72 hrs.), then every two weeks for two doses (at days 22 +/- 72 hrs. and 36 +/- 72 hours). Cells will be harvested for DC administration and a flow cytometry analysis as well as microbiologic analysis including bacterial/fungal cultures and gram stain will be performed prior to infusion. All injections will be based on number of DC, not number of total cells.
It is well-known that smoking is very common in the public. The chronic pain after hysterectomy is 20-40%. The open abdominal hysterectomy ratio is 75% of all hysterectomy operations in our country. We know that the reasons of postoperative acute and chronic pain is multifactorial. One of them is smoking which affects the postoperative pain. The best way of measuring the level of cotinine is assesing the urine of the patient. We collect the first urine after induction.

In this study, we aimed to investigate the correlation between the levels of urine cotinine and the acute and chronic postoperative pain in hysterectomy patents.
Participants will be studied in a randomized trial of 240 mg of Ginkgo biloba as compared to placebo in healthy men and women, at least 75 years old. The trial will last approximately 8 years. The intervention will be considered unsuccessful in those participants who succumb to dementia, including Alzheimer's Disease and vascular dementia. There are four clinical centers: Pittsburgh, PA; Hagerstown, MD; Winston-Salem, NC; and Sacramento, CA; and a Coordinating Center at the University of Washington, Seattle. There will be a clinic visit every 6 months to determine morbidity, mortality and change in cognition that will include repeat of ADAS, CDR, and 10 battery neuropsychological evaluation and informant interview. The primary endpoint is dementia, specifically Alzheimer's disease, secondary endpoint will include the incidence of vascular disease, changes in cognitive function scores over time, total mortality and changes in functional status. The diagnosis of dementia will be based on neuropsychological testing, neurological exam, MRI, functional measurements, and review by a central adjudication committee and classified by DSM IV, NINCDS criteria and ADRTC criteria for vascular disease.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of medicine and is aimed at creation of medications, which can be used both in drug abuse practice and for prophylactic purposes to reduce risk of alcoholism, drug abuse and glue sniffing morbidity. Medication, intended for prevention of onset and/or prevention of development and/or reduction of rate of development of pathological processes, induced by intake of alcohol-containing drinks, contains, at least, one vicinal dithioglycol unithiol in effective amount in form, suitable for peroral introduction. Medication application prevents development of processes of toxic ethanol impact. ^ EFFECT: invention also relates to application of unithiol for preparation of medications in form suitable for peroral introduction, intended for blocking and/or prevention of development and/or reduction of rate of development of pathological processes, induced by intake of alcohol-containing drinks and/or psychoactive substances. ^ 13 cl, 4 dwg, 4 ex
Participants receive hydroxychloroquine PO QD or BID on days 1-21, gemcitabine IV over 90 minutes on days 1 and 8, and docetaxel IV over 1 hours on day 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
The penicillinase-resistant penicillins are available for oral administration and for intramuscular and intravenous injection. The sodium salts of methicillin, oxacillin and nafcillin may be administered parenterally and the sodium salts of cloxacillin, dicloxacillin, oxacillin and nafcillin are available for oral use.

Nafcillin for Injection is available for intramuscular and intravenous injection. The usual I.V. dosage for adults is 500 mg every 4 hours. For severe infections, 1 g every 4 hours is recommended. Administer slowly over at least 30 to 60 minutes to minimize the risk of vein irritation and extravasation.

Bacteriologic studies to determine the causative organisms and their susceptibility to nafcillin should always be performed. Duration of therapy varies with the type and severity of infection as well as the overall condition of the patient, therefore it should be determined by the clinical and bacteriological response of the patient. In severe staphylococcal infections, therapy with nafcillin should be continued for at least 14 days. Therapy should be continued for at least 48 hours after the patient has become afebrile, asymptomatic, and cultures are negative. The treatment of endocarditis and osteomyelitis may require a longer duration of therapy.

Concurrent administration of the penicillinase-resistant penicillins and probenecid increases and prolongs serum penicillin levels. Probenecid decreases the apparent volume of distribution and slows the rate of excretion by competitively inhibiting renal tubular secretion of penicillin. Nafcillin-probenecid therapy is generally limited to those infections where very high serum levels of nafcillin are necessary.

No dosage alterations are necessary for patients with renal dysfunction, including those on hemodialysis. Hemodialysis does not accelerate nafcillin clearance from the blood.

For patients with hepatic insufficiency and renal failure, measurement of nafcillin serum levels should be performed and dosage adjusted accordingly.

For intramuscular gluteal injections, care should be taken to avoid sciatic nerve injury. With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Do not add supplementary medication to Nafcillin for Injection, USP.

Oral preparations of the penicillinase-resistant penicillins should not be used as initial therapy in serious, life-threatening infections (see PRECAUTIONS - General). Oral therapy with the penicillinase-resistant penicillins may be used to follow-up the previous use of a parenteral agent as soon as the clinical condition warrants. For intramuscular gluteal injections, care should be taken to avoid sciatic nerve injury. With intravenous administration, particularly in elderly patients, care should be taken because of the possibility of thrombophlebitis.
CTEPH is one of the leading causes of severe pulmonary hypertension (PH), classified within World Health Organization (WHO) group 4 PH. It is a rare, progressive pulmonary vascular disease that if left untreated, leads to progressively increasing pulmonary vascular resistance (PVR) and eventually right ventricle failure and death. Histopathologic findings including endothelial cell dysfunction and distal pulmonary arterial remodeling are shared between PAH and CTEPH, and PH-specific therapies (that is, riociguat) have shown efficacy in inoperable and persistent/recurrent CTEPH. The endothelin receptor antagonist macitentan offers a different mode of action and addresses an important unmet medical need for an alternative treatment option in this indication. This study will assess the effect of macitentan 75 mg on exercise capacity in CTEPH. The total duration of the study is approximately 6 years. The study comprises of a screening period (at least 14 days and up to 60 days), a double-blind (DB) treatment period (28 weeks \[minimum duration\] up to 3.5 years), an open-label (OL) extension period (starts at end-of-DB-treatment \[EODBT\] and will end for all participants 104 weeks after the last participant has completed DB Week 28). The DB period consists of an 8-week up-titration phase and a maintenance phase. The maintenance phase is divided into a 28-week fixed duration part, at the end of which primary endpoint is assessed, and a variable duration part. The duration of the DB period for an individual participant depends on the timepoint of entry into the study and whether a CEC-confirmed clinical worsening event occurred. Participants who discontinue DB study intervention during the 28-week fixed duration part will be followed until Week 28 in a post-treatment observation period (PTOP).
Sickle cell disease subject cohort randomized 6:2 receiving a single dose of FT-4202 or placebo. The dose of FT-4202/placebo administered will be a dose that was found to be safe in healthy subjects.
A method increases the uptake of nutrients into cells of an individual. The method includes eating a meal. The meal includes the nutrients. The method also includes taking a vasodilator, a blood thinner, or any combinations thereof. In addition, the method includes applying chromium. The method further includes exercising for a duration of time.
BACKGROUND: Deafferentiation pain following brachial plexus root avulsion has been documented to be severe enough to affect activities of daily living in patients. Microsurgical DREZotomy is known to alleviate the symptoms by decreasing the afferent signals transmitted from the spinal cord to sensory cortex.
OBJECTIVES: To document and analyse the effectiveness of DREZotomy and to evaluate the role of 'sensory cortex' in the cause and relief of dysesthetic pain, using fMRI.
MATERIALS AND METHODS: This was a prospective study conducted between 2010 and 2016 and included all patients who underwent DREZotomy for dysesthetic pain following traumatic brachial plexus injury (TBPI). Patients were evaluated both preoperatively and postoperatively with Visual Analogue Scale(VAS), Hospital Anxiety and Depression score (HADS) and SF36 questionnaire and effectiveness of surgery was assessed. Functional magnetic resonance imaging (fMRI) of the brain in resting state was performed before and after surgery and was also compared with controls. Patients underwent standard microsurgical DREZotomy from C5 to D1. Postoperative assessment was done at 6 weeks and 6 months following surgery.
RESULTS: Our series had 18 patients aged between 22 and 63 years. RTA was the most common cause of injury. There was significant decrease in pain at 6 months follow up compared to pre-operative values as assessed by VAS, HADS, SF36 questionnaire. fMRI analysis revealed cluster activations in the sensory, motor cortex and in the right cingulate gyrus in the preoperative group which was higher than in normal controls. In the postoperative group, the size of the resting state activation was significantly reduced.
CONCLUSION: DREZotomy is an effective procedure for TBPI patients. We hypothesize that these fMRI findings reflect the cortical reorganization that occurs not only after injury but also following successful surgery which explains the cause and relief of dyesthetic pain.
Rotational thromboelastometry (ROTEM) is a global hemostasis assay. The diagnosis added value of ROTEM in congenital dysfibrinogenemia remains to be established. The aim of this study was to analyze clot formation by ROTEM in a cohort of dysfibrinogenemic patients and to establish correlations with genotype, clinical features, and coagulation parameters. The study included genetically confirmed congenital dysfibrinogenemia cases (n = 63) and healthy controls ( n  = 50). EXTEM, INTEM, FIBTEM tests were used to measure ROTEM parameters, that is, clotting time (CT), clot formation time (CFT), maximal clot firmness (MCF) and amplitude 10 min after CT (A10). The ISTH bleeding assessment tool was used to determine bleeding episodes. CT (INTEM) was statistically significantly shorter in congenital dysfibrinogenemia patients compared to controls while CFT (EXTEM) was prolonged. Patients's MCF in EXTEM, INTEM, and FIBTEM were similar to controls while A10 (FIBTEM) was statistically significantly lower. Fibrinogen activity was positively correlated with fibrinogen antigen, A10 and MCF in all three assays. Bleeding phenotypes were observed in 23 (36.5%) patients. Only CFT in EXTEM and CT in INTEM were statistically different in patients with bleeding phenotype versus controls. Carriers of the FGA mutation p.Arg35His had a CT (EXTEM) slightly prolonged and a reduced A10 (FIBTEM) compared to controls. Some ROTEM parameters were able to distinguish congenital dysfibrinogenemia patients from controls, and patients with a bleeding phenotype. Prolonged CFT in EXTEM were associated with congenital dysfibrinogenemia and bleeding phenotype. Bleeding episodes in most patients were generally mild and prevalence of thrombosis was very low.
The utility model discloses a subcutaneous implantable sustained-release silica gel rod for antipsychotics, which is characterized in that the subcutaneous implantable sustained-release silica gel rod for antipsychotics comprises a minor segment of medical silicone tube. Antipsychotics having long therapeutic effect, high titer and low therapeutic dose is filled in the medical silicone tube; both ends of the silicone tube are sealed by medical adhesive. The subcutaneous implantable sustained-release silica gel rod for antipsychotics can be used for adopting trochars having small notches with the puncturing and the guiding to be implanted on the inner side of the arm, near the groin position of the abdominal wall, or at the loose position of the hypodermis of the inner side of the thigh after the satisfactory effect on the acute treatment is obtained; 6-7 sustained-release silica gel rods of the utility model can be implanted one time. The subcutaneous implantable sustained-release silica gel rod for antipsychotics has simple configuration, convenient manufacture and operation, enduring therapeutic effect, and economy. The therapeutic effect can persist for 5-6 years by one time implanting; the medicine can be slowly released via the medical adhesive of both ends of the silicone tube, which ensures the effective haemoconcentration to achieve the purpose of maintaining the therapy. The subcutaneous implantable sustained-release silica gel rod for antipsychotics is suitable for the invalids having various schizophrenosis and repeatedly paroxysmal manic symptom.
A health monitor for monitoring the health a user. The system may comprise an edge computing device, a computer, and a health monitor. The health monitor may comprise a sensor module connected to one or more sensors. The health monitor may comprise a data storage logic configured to store the sensor data. The computer may comprise an emergency dispatch module configured to contact an emergency dispatch system; and a healthcare contact module configured to contact a healthcare provider. The health monitor may comprise a command module configured to receive third party contact information; a biographic intake module configured to receive biographic information about the user; and a third-party contact module configured to send a message to a third party; said message comprising sensor module data and the biographic information of the user.
FIELD: medicine, pharmacy, peptides. SUBSTANCE: invention relates to peptide that is a derivative of prosaposin comprising from 14 to 50 amino acids and including the following sequence: Thr-Xaa-Leu-Ile-Asp-Asn-Ala-Thr-Glu-Glu-Ile-Leu-Tyr. Invention relates also to pharmaceutical composition used for therapy of nervous or demyelinizing nervous tissue diseases and comprising indicated peptides. Invention describes also method for neuropathic pain relief in patient, method for stimulation of neuritis growth, inhibition of neurons death, stimulation of myelinization and inhibition of demyelinization of neurons and also method for inhibition of sensitive or motor neuropathy including administration of prosaposin active fragment. Claimed peptides can be used for stimulation of neurites growth, inhibition of nervous system cells death, stimulation of myelinization and inhibition of demyelinization. EFFECT: valuable medicinal properties of peptides. 27 cl, 3 dwg, 6 tbl
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to surgery and radiation therapy, and can be used for application of stent for radiation therapy in combined treatment of malignant tumours of colon complicated by acute obstructive colonic obstruction. During colorectal stenting in endoscopic X-ray surgery under constant X-ray control using a C-arch under an intravenous sedation to assess the possibility of carrying a conductor, the colonoscope is brought to the stenosis more proximally than the tumour. Stenosis is contrasted with liquid water-soluble contrast. Colorectal stent is selected taking into account tumour localization and length of tumour stenosis. Colonoscope channel under vision control and fluoroscopy to constriction zone is carried out through lumen of manipulation catheter metal conductor at distance of not less than 10 cm proximal to upper edge of stenosis. System for delivering a colorectal stent with a radionuclide segment in the form of a radionuclide coating is placed along the guide into a narrowing region. Stent is exposed under fluoroscopy control. It is followed by abdominal control roentgenography. Siphon enema is then placed with control of intestinal contents.EFFECT: method provides improved clinical results in patients suffering colorectal cancer complicated by acute obstructive colonic obstruction: reduced number of postoperative complications, reduced postoperative bed-day, postoperative lethality, avoiding colostomy - by modernizing a colorectal stent aimed at combining its drainage capacity with additional therapeutic effects.1 cl, 2 ex
Patients receive MV-NIS intrapleurally on day 1. Treatment repeats every 28 days for up to 6 courses in absence of disease progression or unacceptable toxicity.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Based on pooled data across all indications, the most frequent adverse reactions for both adult and pediatric populations observed in clinical trials are abdominal pain, diarrhea, nausea, vomiting and dysgeusia. Also reported were dyspepsia, liver function test abnormal, anaphylactic reaction, candidiasis, headache, insomnia, and rash.

Gastrointestinal Adverse Reactions

In the acute exacerbation of chronic bronchitis and acute maxillary sinusitis studies overall gastrointestinal adverse reactions were reported by a similar proportion of patients taking either clarithromycin immediate-release tablets or clarithromycin extended-release tablets; however, patients taking clarithromycin extended-release tablets reported significantly less severe gastrointestinal symptoms compared to patients taking clarithromycin immediate-release tablets. In addition, patients taking clarithromycin extended-release tablets had significantly fewer premature discontinuations for drug-related gastrointestinal or abnormal taste adverse reactions compared to clarithromycin immediate-release tablets.

All-Cause Mortality in Patients with Coronary Artery Disease 1 to 10 Years Following Clarithromycin Exposure

In one clinical trial evaluating treatment with clarithromycin on outcomes in patients with coronary artery disease, an increase in risk of all-cause mortality was observed in patients randomized to clarithromycin. Clarithromycin for treatment of coronary artery disease is not an approved indication. Patients were treated with clarithromycin or placebo for 14 days and observed for primary outcome events (e.g., all-cause mortality or non-fatal cardiac events) for several years.1 A numerically higher number of primary outcome events in patients randomized to receive clarithromycin was observed with a hazard ratio of 1.06 (95% confidence interval 0.98 to 1.14). However, at follow-up 10 years post-treatment, there were 866 (40%) deaths in the clarithromycin group and 815 (37%) deaths in the placebo group that represented a hazard ratio for all-cause mortality of 1.10 (95% confidence interval 1.00 to 1.21). The difference in the number of deaths emerged after one year or more after the end of treatment.

The cause of the difference in all-cause mortality has not been established. Other epidemiologic studies evaluating this risk have shown variable results [see Warnings and Precautions (5.5)].
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to pharmaceutical composition eliciting antidepressant effect and method for it preparing. Pharmaceutical composition comprises indole derivative and special additions. As an indole derivative pharmaceutical composition comprises pyrazidol or incazan, or tetrindole. Special additions are taken among the following groups: group including starch, cellulose or its derivative; group including stearic acid, stearates; group including sugar, lactose or its derivative taken in the definite ratio of components. Pharmaceutical composition represents solid medicinal form. Also, invention involves method for preparing the claimed pharmaceutical composition. Invention provides preparing pharmaceutical composition corresponding to requirements for pharmaceutical agent, elicits the enhanced stability in storage. The claimed method for preparing pharmaceutical composition provides maximal yield and stability of drug. EFFECT: improved and valuable medicinal and pharmaceutical properties of composition. 10 cl, 12 ex
The invention relates to clinical application of traditional Chinese medicines, in particular to the field of application of a traditional Chinese medicine composition in preventing and treating alcoholic fatty liver. A traditional Chinese medicine composition for preventing and treating alcoholic fatty liver is characterized in that the composition is prepared from the following raw material medicines in parts by weight: 5-25 parts of cassia seed, 5-20 parts of lotus leaf, 5-20 parts of dried orange peel and 10-50 parts of oyster. Further, 10-20 parts of semen cassiae, 10-15 parts of lotus leaves, 10-12 parts of dried orange peel and 20-40 parts of oysters. Furthermore, the composition can be made into tablet, capsule, granule, mixture, oral liquid, and injection with pharmaceutically acceptable adjuvants. In the formula, the cassia seed is taken as a monarch drug to achieve the effects of clearing liver and dissipating heat, the lotus leaf is fragrant and is used for promoting diuresis, the dried orange peel is used for tonifying spleen, eliminating dampness and phlegm, and the raw oyster is used for calming the liver and dissipating stagnation and is taken as an adjuvant drug together. The whole formula has the effects of clearing heat and promoting diuresis, and reducing phlegm and resolving masses. The traditional Chinese medicine composition has homology of medicine and food, and is a prescription with good safety and curative effect.